Atherosclerosis · 2026
Effect of in-hospital initiation of alirocumab on clinical outcomes in Chinese ACS patients: findings from the Chinese Cardiovascular Association (CCA) Database-Chest Pain Center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Yani, Li Dandan, Shan Dongkai, Wang Ying, Tuo Xiaodan, Li Zongxing, Chen Jie, Chen Yundai
Аннотация
BACKGROUND AND AIMS: To evaluate the real-world impact of early in-hospital Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) inhibitor initiation on clinical outcomes in Chinese acute coronary syndrome (ACS) patients.
METHODS: This retrospective study analyzed ACS patients (2021-2023) from the CCA Database-Chest Pain Center, comparing alirocumab-treated (n = 6414) and control (n = 25,656) groups after propensity score matching. Outcomes included 1-year major adverse cardiovascular events (MACE) (defined as the composite of non-fatal myocardial infarction, non-fatal ischemic stroke, all-cause mortality, or any coronary revascularization) via Kaplan-Meier analysis and low-density lipoprotein cholesterol (LDL-C) goal attainment (<1.4 mmol/L) at 1/3/6 months. Logistic regression was performed to identify predictors.
RESULTS: The alirocumab group showed a significantly lower MACE incidence rate during 1-year of follow-up (2.76 vs 3.95 per 100 person-years, p = 0.003). At follow-up, LDL-C measurements were available in 293, 123, and 33 patients in the alirocumab group and 1759, 984, and 424 patients in the control group at 1, 3, and 6 months, respectively. More patients in the alirocumab group reached the LDL-C goal at 1-month (58.02% vs. 24.33%, p < 0.001). This trend remained consistent during the subsequent 3-month (52.85% vs. 23.88%, p < 0.001) and 6-month follow-up (51.52% vs. 26.18%, p = 0.002). Participation in the ACS Pathway Optimization project (OR = 0.49; 95% CI 0.29, 0.77; p = 0.004), in-hospital initiation of alirocumab (OR = 0.62; 95% CI 0.48, 0.78; p < 0.001), male (OR = 0.71; 95% CI 0.58, 0.87; p < 0.001) were significantly negatively associated with the occurrence of MACE event, and in-hospital initiation of alirocumab (OR = 4.29; 95% CI 3.23, 5.71; p < 0.001), male (OR = 1.47; 95% CI 1.09, 2.00; p = 0.014), hypertension (OR = 1.31; 95% CI 1.06, 1.63; p = 0.012) and lipid lowering treatment statin and ezetimibe (OR = 2.20; 95% CI 1.58, 3.07; p < 0.001) were significantly positively associated with 1-month LDL-C goal attainment.
CONCLUSION: In-hospital initiation of alirocumab was associated with a lower risk of MACE and with higher LDL-C goal attainment in China real-world ACS patients.
METHODS: This retrospective study analyzed ACS patients (2021-2023) from the CCA Database-Chest Pain Center, comparing alirocumab-treated (n = 6414) and control (n = 25,656) groups after propensity score matching. Outcomes included 1-year major adverse cardiovascular events (MACE) (defined as the composite of non-fatal myocardial infarction, non-fatal ischemic stroke, all-cause mortality, or any coronary revascularization) via Kaplan-Meier analysis and low-density lipoprotein cholesterol (LDL-C) goal attainment (<1.4 mmol/L) at 1/3/6 months. Logistic regression was performed to identify predictors.
RESULTS: The alirocumab group showed a significantly lower MACE incidence rate during 1-year of follow-up (2.76 vs 3.95 per 100 person-years, p = 0.003). At follow-up, LDL-C measurements were available in 293, 123, and 33 patients in the alirocumab group and 1759, 984, and 424 patients in the control group at 1, 3, and 6 months, respectively. More patients in the alirocumab group reached the LDL-C goal at 1-month (58.02% vs. 24.33%, p < 0.001). This trend remained consistent during the subsequent 3-month (52.85% vs. 23.88%, p < 0.001) and 6-month follow-up (51.52% vs. 26.18%, p = 0.002). Participation in the ACS Pathway Optimization project (OR = 0.49; 95% CI 0.29, 0.77; p = 0.004), in-hospital initiation of alirocumab (OR = 0.62; 95% CI 0.48, 0.78; p < 0.001), male (OR = 0.71; 95% CI 0.58, 0.87; p < 0.001) were significantly negatively associated with the occurrence of MACE event, and in-hospital initiation of alirocumab (OR = 4.29; 95% CI 3.23, 5.71; p < 0.001), male (OR = 1.47; 95% CI 1.09, 2.00; p = 0.014), hypertension (OR = 1.31; 95% CI 1.06, 1.63; p = 0.012) and lipid lowering treatment statin and ezetimibe (OR = 2.20; 95% CI 1.58, 3.07; p < 0.001) were significantly positively associated with 1-month LDL-C goal attainment.
CONCLUSION: In-hospital initiation of alirocumab was associated with a lower risk of MACE and with higher LDL-C goal attainment in China real-world ACS patients.